This competitive renewal application for a Specialized Program of Research Excellence (SPORE) in Cervical Cancer at the Johns Hopkins University School of Medicine, University of Alabama at Birmingham and University of Colorado brings together a highly interactive, multidisciplinary, and inter-institutional program of translational research in cervical cancer. The SPORE includes four integrated projects spanning the fields of prevention and treatment of cervical cancer. Project I: L1 Capsomeres as a Next Generation Preventive HPV Vaccine, led by Robert Garcea, M.D., Richard Roden, Ph.D., and Warner Huh, M.D. Project II: Development of a Pan-Oncogenic HPV Preventive Vaccine, led by Richard Roden, Ph.D., and Warner Huh, M.D. Project III;A phase I clinical trial to assess the immunogenicity, safety, tolerability and efficacy of HPV DNA-Vaccinia prime booster vaccination with locally applied TLR agonists in patients with HPV-16+ cervical intraepithelial neoplasia 3 (CIN3), led by Cornelia Trimble, M.D., Drew Pardoll, M.D., Ph.D. and T.-C. Wu, M.D., Ph.D. Project IV: A phase I clinical trial to assess the safety and immunogenicity of repeated, cluster particle-mediated epidermal delivery (PMED) of the DNA vaccine, pNGVL4a-CRT-E7(detox), in patients with operable Stage IB1 cervical cancer associated with HPV-16, led by Ronald Alvarez, M.D., Connie Trimble, M.D. and T.-C. Wu, M.D., Ph.D. These four projects are supported by four Cores that provide critical and supportive infrastructure essential to efficient and effective translational research. The Administration/ Communication Core (Core A) led by T. C. Wu, M.D., Ph.D. and Edward Partridge, M.D, the Biostatistics/ Data Management Core (Core B) led by Mei-Cheng Wang, Ph.D., and Sreelatha Meleth, Ph.D., the Tissue /Pathology Core (Core C) led by Brigitte Ronnett, M.D. and Lawrence Lamb, Ph.D. and the Immunology Core (Core D) led by Raphael Viscidi, M.D. and Chien-Fu Hung, Ph.D. The SPORE also includes a Developmental Research Program for rapid funding of novel research ideas and a Career Development Program to facilitate career development of individuals with interest in translational cervical cancer research.

Public Health Relevance

The intent of our program is to reduce the incidence of cervical cancer and to improve the outcome in patients with HPV associated cervical cancer and their precursor lesions by developing innovative vaccination strategies for the prevention and treatment of cervical cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098252-10
Application #
8537828
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Kuzmin, Igor A
Project Start
2003-09-30
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$2,150,500
Indirect Cost
$565,798
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wang, Joshua W; Hung, Chein-Fu; Huh, Warner K et al. (2015) Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) 8:95-104
Banet, Natalie; Gown, Allen M; Shih, Ie-Ming et al. (2015) GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol 39:101-8
Wu, Chao-Yi; Yang, Li-Hua; Yang, Huang-Yu et al. (2014) Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 20:644-57
Zhao, Rui-Xun; Xu, Zhi-Xiang (2014) Targeting the LKB1 tumor suppressor. Curr Drug Targets 15:32-52
Kwak, Kihyuck; Jiang, Rosie; Wang, Joshua W et al. (2014) Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One 9:e97232
Coughlin, Kathleen; Anchoori, Ravi; Iizuka, Yoshie et al. (2014) Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20:3174-86
Wang, Joshua W; Jagu, Subhashini; Wang, Chenguang et al. (2014) Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One 9:e101576
Paul, Proma; Tanner, Amanda E; Gravitt, Patti E et al. (2014) Acceptability of HPV vaccine implementation among parents in India. Health Care Women Int 35:1148-61
Soong, Ruey-Shyang; Song, Liwen; Trieu, Janson et al. (2014) Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One 9:e93162
Zhang, Huang-Ge; Grizzle, William E (2014) Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 184:28-41

Showing the most recent 10 out of 188 publications